Today: 3 April 2026
Meta stock slips as Senate “SCAM Act” targets scam ads and regulators circle
4 February 2026
2 mins read

Meta stock slips as Senate “SCAM Act” targets scam ads and regulators circle

New York, Feb 4, 2026, 10:50 (EST) — Regular session

  • Shares of Meta dropped roughly 1.7% in early trading amid lawmakers’ efforts to tighten advertising regulations
  • U.S. senators have introduced the “SCAM Act,” aiming to compel platforms to verify advertisers, backed by enforcement from the FTC
  • India’s highest court also cautioned that WhatsApp might face restrictions on how it shares user data within Meta

Meta Platforms shares dropped 1.7% to $679.86 Wednesday morning, extending a volatile stretch for the Facebook and Instagram parent. The selloff followed a bipartisan Senate bill proposal aimed at cracking down on scam ads. The legislation would force social media companies to verify advertisers and give enforcement powers to the Federal Trade Commission and state attorneys general. Reuters

The bill, dubbed the Safeguarding Consumers from Advertising Misconduct Act — or the SCAM Act — hits a nerve with investors wary of swift market moves. It targets the very engine of the system: ads sold en masse, typically to small businesses that prioritize speed over red tape.

The timing is notable, coming as the market has adopted a “guilty until proven innocent” stance toward big tech whenever growth might be squeezed—be it from regulation, ad demand, or the expenses tied to developing artificial intelligence. For Meta, this is crucial since ad revenue remains its lifeblood, despite the current focus on “AI.”

Pressure isn’t only building in the U.S. On Tuesday, India’s Supreme Court signaled it might reinstate a ban on WhatsApp sharing user data with other Meta companies. Two lawyers in court described the app’s privacy policy as “very cleverly designed to mislead users.” India represents Meta’s largest market by user count. WhatsApp has warned that a ban there could force it to halt or reverse certain features. Reuters

The broader market hasn’t lent any support. A selloff sweeping through software and data stocks is driven by worries that emerging AI tools could erode pricing power in tech segments once considered untouchable just a year ago. “We are now in an environment where the sector isn’t just guilty until proven innocent but is now being sentenced before trial,” said J.P. Morgan analyst Toby Ogg. Reuters

Wall Street showed jitters on that front. The S&P 500 dropped 0.84% Tuesday, while the Nasdaq slipped 1.43% amid concerns over AI-driven competition and its potential impact on tech profit margins. “Many areas, especially around AI, are priced for perfection,” said John Campbell, senior portfolio manager at Allspring Global Investments. Reuters

Meta enters this period with a key concern: spending. The company raised its 2026 capital expenditure forecast last week, now expecting $115 billion to $135 billion as it pursues what CEO Mark Zuckerberg dubbed “personal superintelligence.” “This is going to be a big year,” Zuckerberg told analysts on the call. Reuters

This matters because stricter ad regulations don’t just lead to worse headlines. They also bring added friction when onboarding advertisers, increased screening expenses, and greater legal risks if a problematic ad slips past — all as investors watch closely to see if AI-driven budgets can pay off quickly enough.

Traders face a key practical issue: how much of this will actually become law, and on what timeline. Bills often start out clean but can end up rewritten, narrowed, or stuck in limbo. Meanwhile, court battles can drag on without impacting near-term revenue.

The downside is clear. Stricter U.S. enforcement combined with a fresh crackdown in India could pinch Meta on both fronts — its ad revenue and the data usage that powers ad targeting — dealing a blow to sentiment just as the market grows jittery over big tech risks.

Investors are turning to megacap earnings for hints on ad demand and AI spending control. Alphabet reports after the close, followed by Amazon on Thursday. Meanwhile, markets await a clear date for the delayed U.S. labor-market data release. Reuters

Stock Market Today

  • Sun Pharma Shares Under Pressure After Trump Imposes Tariffs on Imported Drugs
    April 3, 2026, 4:11 AM EDT. Sun Pharma shares will be closely watched after President Trump issued an executive order imposing 100% tariffs on imported branded pharmaceuticals unless manufacturers cut prices or produce locally. Although generic drugs are exempt and some big pharma firms have negotiated to avoid tariffs, mid-sized companies like Sun Pharma face risks. Jefferies notes Sun Pharma earns about 20% of its revenue from innovative drugs produced mainly in South Korea, the EU, or the U.S.-regions subject to a 15% tariff, capping potential impact. The stock dropped nearly 2% to ₹1,694.65 on April 2 but showed signs of buying interest Friday, suggesting possible short-term recovery towards ₹1,730-₹1,750. Immediate support is at ₹1,640, key for sustaining any rebound.
AMD stock price slides 14% after outlook flags a slower quarter — and AI nerves bite
Previous Story

AMD stock price slides 14% after outlook flags a slower quarter — and AI nerves bite

Shopify stock drops again as ChatGPT checkout fees fuel fresh Wall Street split
Next Story

Shopify stock drops again as ChatGPT checkout fees fuel fresh Wall Street split

Go toTop